Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
|Articles|February 9, 2022
Pharmacy Clinical Pearl of the Day: Golfer’s Elbow
Author(s)Saro Arakelians, PharmD
Pain from golfer's elbow may spread into the forearm and wrist.
Advertisement
Clinical Pearl of the Day: Golfer’s Elbow
Golfer's elbow is a condition that causes pain as the tendons of the forearm muscles attach to the bony bump on the inside of the elbow.
Insight:
- The pain from golfer's elbow may spread into the forearm and wrist.
- Golfer's elbow is similar to tennis elbow, which occurs on the outside of the elbow.
- The pain of golfer's elbow doesn't have to keep people off the course or away from their favorite activities.
- Rest and appropriate treatment can get those affected back into the swing of things.
- Symptoms may include pain, weakness, stiffness, and numbness in the affected area.
- Diagnosis may include MRI or X-ray studies.
- Treatment may include pain medications, surgery, or physical therapy.
Sources:
Advertisement
Related to this article
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
Beyond Prescription Volume: Measuring the Pharmacist’s Value
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5